PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.18%
Negative revenue growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-13.34%
Negative gross profit growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-340.87%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-340.87%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-148.50%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-145.28%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-145.28%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.27%
Share change of 0.27% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if the modest difference matters long-term.
-0.36%
Diluted share reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
-32.18%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
3.33%
FCF growth of 3.33% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
1118.33%
5Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.63%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
654.32%
3Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.63%. Joel Greenblatt might see a short-term competitive advantage at play.
-339.33%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-2397.94%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-604.60%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-315.13%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-278.03%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-165.58%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
3215.35%
Equity/share CAGR of 3215.35% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
2681.11%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 4.42%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
137.62%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 4.65%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.81%
AR growth of 5.81% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
35.48%
Inventory growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos suspects major issues in demand forecasting or potential obsolescence risk.
2.87%
Asset growth of 2.87% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
0.31%
BV/share growth of 0.31% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
7.25%
Debt growth of 7.25% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
10.80%
R&D growth of 10.80% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
20.12%
SG&A growth of 20.12% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.